15 hours ago · Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide maker Novo Nordisk—with its blockbuster molecule tirzepatide. Now, with a pipeline chock full of ...

Nov 8, 2023 · Zepbound is the first and only approved treatment activating two incretin hormone receptors, GIP and GLP-1, to tackle an underlying cause of excess weight.

20 hours ago · Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the drugmaker came out with a mostly better-than-expected 2025 forecast.

1 day ago · Eli Lilly expects to read out results from a study in people with obesity and osteoarthritis of the knee in 2025.

Jun 26, 2023 · At 24 weeks, retatrutide (1 mg, 4 mg, 8 mg or 12 mg) met the primary endpoint for the efficacy estimand in participants living with obesity or overweight i without diabetes, demonstrating a mean weight reduction up to 17.5% (41.2 lb. or 18.7 kg) ii.

See the difference the right care can make for obesity. Convenient - Get answers, test results, care plans, and prescriptions. All without waiting rooms or traffic.* Specialized - Talk to …

Nov 13, 2024 · Weekly tirzepatide (Zepbound ® and Mounjaro ®) injections (pooled 5 mg, 10 mg, 15 mg doses) significantly reduced the risk of progression to type 2 diabetes in adults with pre-diabetes and obesity or overweight, compared with placebo, over 176 weeks.

Nov 2, 2023 · Eli Lilly is in “all-of-the-above mode” in obesity, with the research teams moving as fast as possible to advance an oral candidate and build a portfolio of complementary treatments.

Lilly partners with clinical trial volunteers to develop new weight management treatment options. Learn more about obesity research and find Lilly trials here.

18 hours ago · Eli Lilly’s earnings, shares lifted by obesity drug sales The drugmaker’s financial forecasts topped Wall Street’s expectations, reassuring investors after it overestimated demand for its weight loss medicines in January.